verapamil has been researched along with Obesity in 23 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have shown previously that the combination of a long-acting, non-sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor (trandolapril) and the Ca2+ channel blocker verapamil improve insulin-stimulated glucose transport in skeletal muscle of the obese Zucker rat, a model of insulin resistance, hyperinsulinemia, and dyslipidemia." | 7.70 | Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. ( Dal Ponte, DB; Fogt, DL; Henriksen, EJ; Jacob, S, 1998) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0." | 6.70 | Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. ( Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " James Women Take Heart (WTH; women without coronary disease at baseline), Women's Ischemia Syndrome Evaluation (women with signs/symptoms of ischemia at baseline), and the INternational VErapamil-Trandolapril STudy (INVEST; women with coronary artery disease and hypertension at baseline), totaling 15,108 adult women with no hypertension, non-RH (blood pressure [BP] ≥140/90 mmHg on ≤2 drugs or BP <140/90 mmHg on 1-3 drugs), or aRH (BP ≥140/90 mmHg on ≥3 drugs or anyone on ≥4 drugs) at baseline." | 3.83 | Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. ( Cooper-DeHoff, RM; Gong, Y; Gulati, M; Handberg, E; Huo, T; Merz, CN; Pepine, CJ; Smith, SM, 2016) |
| " Forearm blood flow responses to graded doses of acetylcholine, sodium nitroprusside, and verapamil were assessed by strain-gauge plethysmography in patients with obesity-related MetS (n = 20) and in matched controls (n = 18) before and after intra-arterial infusion of insulin (0." | 3.76 | Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. ( Cardillo, C; Galli, A; Lauro, D; Mores, N; Porzio, O; Rovella, V; Schinzari, F; Tesauro, M, 2010) |
| "We have shown previously that the combination of a long-acting, non-sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor (trandolapril) and the Ca2+ channel blocker verapamil improve insulin-stimulated glucose transport in skeletal muscle of the obese Zucker rat, a model of insulin resistance, hyperinsulinemia, and dyslipidemia." | 3.70 | Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. ( Dal Ponte, DB; Fogt, DL; Henriksen, EJ; Jacob, S, 1998) |
| "Calcium channel blockers, verapamil or felodipine, were given to genetically obese 6 and 11-month-old female SHHF/Mcc-facp (SHHF: Spontaneous Hypertension Heart Failure) rats for 8 weeks to investigate their effects on glucose and lipid metabolism and obesity." | 3.70 | Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats. ( Hoepf, T; McCune, SA; Park, SC; Radin, MJ, 1999) |
| "We have used an animal model of insulin resistance-the obese Zucker (fa/fa) rat-to test whether oral administration of the non-sulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, trandolapril, alone or in combination with the Ca2+-channel blocker, verapamil, can induce a beneficial effect on insulin-stimulated glucose transport and metabolism in skeletal muscle." | 3.69 | Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1996) |
| " In order to clarify whether calcium-antagonist effect was directed at the level of pancreatic insulin secretion or hepatic insulin extraction and further investigate the pathogenesis of hyperinsulinemia in obesity, an oral glucose tolerance test (OGTT) was performed in basal conditions and during a Verapamil infusion (VE, 5 mg/h x 3." | 3.68 | Calcium antagonists and hormone release. VIII. Effects of verapamil infusion on C-peptide to insulin molar ratio in normal subjects and obese subjects with normal glucose tolerance. ( De Marinis, L; Fiumara, C; Folli, G; Mancini, A; Sammartano, L; Sandric, S; Valle, D; Zuppi, P, 1992) |
| "To evaluate the mechanism of obesity-induced changes in pharmacokinetics and pharmacodynamics of verapamil observed in humans, single-dose and steady-state kinetic/dynamic studies in obese Zucker rats were done." | 3.67 | Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ( Abernethy, DR; Todd, EL, 1986) |
| "Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate." | 2.73 | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP; Nakou, E; Tselepis, AD, 2008) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0." | 2.70 | Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. ( Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " Islets from both genetic models showed a left-shifted glucose dose-response curve for insulin release (concentrations for half-maximal release, 5 to 6 mmol/L v 12 to 13 mmol/L in LA/N lean littermates and 3 mmol/L v 10 mmol/L in lean SHR/N)." | 1.28 | Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose. ( Recant, L; Timmers, KI; Voyles, NR, 1992) |
| "Verapamil (0." | 1.27 | Verapamil pharmacodynamics and disposition in obese hypertensive patients. ( Abernethy, DR; Schwartz, JB, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, HW | 1 |
| Park, H | 1 |
| Semple, IA | 1 |
| Jang, I | 1 |
| Ro, SH | 1 |
| Kim, M | 1 |
| Cazares, VA | 1 |
| Stuenkel, EL | 1 |
| Kim, JJ | 1 |
| Kim, JS | 1 |
| Lee, JH | 1 |
| Czaja, MJ | 1 |
| Smith, SM | 1 |
| Huo, T | 1 |
| Gong, Y | 1 |
| Handberg, E | 1 |
| Gulati, M | 1 |
| Merz, CN | 1 |
| Pepine, CJ | 2 |
| Cooper-DeHoff, RM | 2 |
| Nakou, E | 1 |
| Filippatos, TD | 1 |
| Liberopoulos, EN | 1 |
| Tselepis, AD | 1 |
| Kiortsis, DN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Schinzari, F | 1 |
| Tesauro, M | 1 |
| Rovella, V | 1 |
| Galli, A | 1 |
| Mores, N | 1 |
| Porzio, O | 1 |
| Lauro, D | 1 |
| Cardillo, C | 1 |
| Rubio-Guerra, AF | 1 |
| Lozano-Nuevo, JJ | 1 |
| Vargas-Ayala, G | 1 |
| Rodríguez-López, L | 1 |
| Ramos-Brizuela, LM | 1 |
| Escalante-Acosta, BA | 1 |
| Scholze, J | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Uretsky, S | 1 |
| Messerli, FH | 1 |
| Bangalore, S | 1 |
| Champion, A | 1 |
| Zhou, Q | 1 |
| Iskenderov, BG | 1 |
| Burmistrova, LF | 1 |
| Berenshteĭn, NV | 1 |
| Lokhina, TV | 1 |
| Jacob, S | 2 |
| Henriksen, EJ | 2 |
| Fogt, DL | 2 |
| Dietze, GJ | 1 |
| Streier, K | 1 |
| Dal Ponte, DB | 1 |
| Park, SC | 1 |
| Radin, MJ | 1 |
| Hoepf, T | 1 |
| McCune, SA | 1 |
| White, WB | 1 |
| Elliott, WJ | 1 |
| Johnson, MF | 1 |
| Black, HR | 1 |
| Timmers, KI | 1 |
| Voyles, NR | 1 |
| Recant, L | 1 |
| De Marinis, L | 1 |
| Mancini, A | 1 |
| Zuppi, P | 1 |
| Sammartano, L | 1 |
| Valle, D | 1 |
| Fiumara, C | 1 |
| Sandric, S | 1 |
| Folli, G | 1 |
| Black, MA | 1 |
| Fournier, LA | 1 |
| Heick, HM | 1 |
| Bégin-Heick, N | 1 |
| Abernethy, DR | 2 |
| Schwartz, JB | 1 |
| Miilunpalo, S | 1 |
| Saarinen, R | 1 |
| Marniemi, J | 1 |
| Lehtonen, A | 1 |
| Draznin, B | 1 |
| Sussman, KE | 1 |
| Eckel, RH | 1 |
| Kao, M | 1 |
| Yost, T | 1 |
| Sherman, NA | 1 |
| Todd, EL | 1 |
| Weidinger, H | 1 |
| Mohr, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for verapamil and Obesity
| Article | Year |
|---|---|
Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weights and Measures; C-R | 2008 |
Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy.
Topics: Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance; | 2006 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation | 2007 |
Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Calcium Channel Blocke | 2001 |
17 other studies available for verapamil and Obesity
| Article | Year |
|---|---|
Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers.
Topics: Animals; Autophagy; Calcium; Calcium Channel Blockers; Cytosol; Echocardiography; Hep G2 Cells; Hepa | 2014 |
A new mechanism of lipotoxicity: Calcium channel blockers as a treatment for nonalcoholic steatohepatitis?
Topics: Animals; Autophagy; Calcium Channel Blockers; Humans; Lysosomes; Metabolic Diseases; Obesity; Phagos | 2015 |
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Drug Resistance; Fema | 2016 |
Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome.
Topics: Acetylcholine; Analysis of Variance; Ascorbic Acid; Chromatography, High Pressure Liquid; Dose-Respo | 2010 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biological Transport; Calcium Channel Blockers; F | 1996 |
[Obesity in the service of Justice. New drug-combination leads to protection of the kidney].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Diabet | 1997 |
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Captopri | 1998 |
Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats.
Topics: Age Factors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium C | 1999 |
Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose.
Topics: Animals; Blood Glucose; Blotting, Western; Cell Separation; Cells, Cultured; Diabetes Mellitus, Expe | 1992 |
Calcium antagonists and hormone release. VIII. Effects of verapamil infusion on C-peptide to insulin molar ratio in normal subjects and obese subjects with normal glucose tolerance.
Topics: Adult; Blood Glucose; C-Peptide; Glucose Tolerance Test; Humans; Infusions, Intravenous; Insulin; In | 1992 |
Different insulin-secretory responses to calcium-channel blockers in islets of lean and obese (ob/ob) mice.
Topics: Animals; Colforsin; Dantrolene; Glucose; Insulin; Insulin Secretion; Ion Channels; Islets of Langerh | 1988 |
Verapamil pharmacodynamics and disposition in obese hypertensive patients.
Topics: Adult; Blood Pressure; Electrocardiography; Female; Humans; Hypertension; Infusions, Intravenous; Ma | 1988 |
Erythrocyte cation transport in obesity, hypertension, and during antihypertensive drug therapy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Cations; Erythrocytes | 1989 |
Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia.
Topics: Adipose Tissue; Adult; Biopsy; Calcium; Cytosol; Deoxyglucose; Female; Glyburide; Humans; Hyperinsul | 1988 |
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.
Topics: Animals; Blood Pressure; Blood Proteins; Body Weight; Disease Models, Animal; Female; Kinetics; Obes | 1986 |
[Serum glucose and immunoreactive insulin during or without treatment with Th 1165a und Isoptin in gravid women (author's transl)].
Topics: Adrenergic beta-Agonists; Blood Glucose; Diabetes Mellitus; Drug Therapy, Combination; Female; Gluco | 1973 |